Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at a locally advanced stage, where cisplatin-based chemoradiotherapy is standard but still results in high recurrence rates. Immunotherapy is promising for HNSCC due to its high mutational burden, and adding PD-1 inhibitors to induction chemotherapy has improved responses without added toxicity. Radiotherapy can further stimulate antitumor immunity. Iparomlimab and Tuvonralimab, a dual anti-PD-1/CTLA-4 antibody, has shown strong activity across several solid tumors, and early studies suggest synergy with hypofractionated radioth

Trial Details

NCT ID
NCT07447570
Phase
PHASE2
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Iparomlimab and Tuvonralimab injection
  • Hypofractionated Radiotherapy
  • Chemotherapy
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Signed a written informed consent form and understands and agrees to comply with the study requirements and visit schedule.
  • Male or female subjects aged ≥18 and ≤75 years at the time of signing informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1.
  • Histologically or cytologically confirmed stage III-IVB head and neck squamous cell carcinoma as assessed by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →